Insider buying at the PIPE price suggests management views the stock as undervalued. The PIPE provides balance sheet support, reducing near-term financing risk. Monitor for pipeline catalysts (phase updates) that could drive re-rating.
QTTB drugs
QTTB drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $12.64entry
- T+1 · 6mo ago −3.56%α −2.84% · $12.19
- T+5 · 5mo ago −5.93%α −2.97% · $11.89
- T+20 · 5mo ago −0.32%α +1.25% · $12.60
- T+60 · 3mo ago +28.01%α +26.89% · $16.18
Price Chart
How similar events traded
Executive Summary
Directors OrbiMed Advisors and Xu Diyong each purchased $10M of QTTB common stock at $8/share on May 28, 2026, for a total of $20M (10.1% of market cap). These open-market purchases coincide with a PIPE offering disclosed in the May 27 8-K, indicating insider participation and strong confidence at the offering price.
Key Financial Metrics
Key Facts
- OrbiMed Advisors LLC and Xu Diyong each bought 1,250,000 shares at $8.00 on 2026-05-28, total $20M.
- Total insider purchase equals ~10.1% of QTTB's $198M market cap.
- Purchases follow a Securities Purchase Agreement (8-K filed 2026-05-27) for a PIPE offering at the same $8 price.
- Both buyers are directors and 10% owners, amplifying the signal.
Financial Impact
Insiders invested $20M at $8/share, representing 10.1% of market cap; PIPE likely raises additional capital from other investors.
Risk Factors
- PIPE dilutes existing shareholders; new shares represent a significant overhang.
- Clinical-stage biotech risk; pipeline failure could impair recovery.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-QTTB-1780362955879 |
Track record
23 reports on QTTB
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +48.47% at T+60 after the Jul 14, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $8.29 Now $8.29 −0.00% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.47 Now $8.29 −2.13% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $8.71 Now $8.29 −4.82% settles Dec 15
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $8.97 Now $8.29 −7.58% settles Dec 3
- Oct 28, 202619d ago SC 13G Neutral 4/10 Entry $9.06 Now $8.29 −8.50% settles Nov 25
- Oct 9, 20265w ago SC 13G Neutral 4/10 Entry $8.74 to $9.36 Now $8.29 −5.15% ▲ +7.09% +10.36% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $8.27 to $8.71 Now $8.29 +0.24% ▲ +5.32% +4.05% vs SPY
- Sep 14, 20269w ago 8-K Neutral 3/10 Entry $10.91 to $8.74 Now $8.29 −24.01% ▼ −19.89% −22.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers